Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

of a Phase 3 registration trial with perifosine in refractory advanced colorectal cancer by Keryx. - April 15, 2010: Positive Scientific Advice from the EMA for the Phase 3 program with perifosine in multiple myeloma. Data from ongoing Phase 3 study, sponsored by Keryx, can be used to register perifosine in multiple myeloma in Europe. - April 20, 2010: Presentations of preclinical data on Erk inhibitor, AEZS-131, and Erk/PI3K dual inhibitor, AEZS-132, as well as preclinical data from a study sponsored by the National Institutes of Health with perifosine in oncology at the American Association for Cancer Research Annual Meeting in Washington, D.C. - April 20, 2010: Completion of a $15.0 million registered direct offering with certain institutional investors. - April, 23, 2010: Company regained compliance with Nasdaq's minimum bid price listing requirement. - May 6, 2010: Company receives orphan-drug designation from the FDA for AEZS-108 in ovarian cancer. - May 12, 2010: FDA approves the Company's Investigational New Drug (IND) application for AEZS-108 in LHRH-receptor positive urothelial (bladder) cancer.

Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "This has been a very exciting quarter as we made great strides in the development of our lead oncology compound, perifosine, now in Phase 3 registration trials for multiple myeloma and refractory advanced colorectal cancer. Furthermore, the different designations recently granted by the FDA in both indications and the EMA's positive Scientific Advice for multiple myeloma, will accelerate as well as facilitate the future review and marketing authorization processes in North America and Europe."


SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... Forecasts Growth of More Than 40%, NEW ... /Xinhua-PRNewswire-,FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") ... generic and brand,bio-pharmaceutical products in China, announced today ... to exceed 40%., According to recent sales ...
... Genome,Sciences, Inc. (Nasdaq: HGSI ) announced today that ... be webcast and may be accessed at, http://www.hgsi.com , ... of Human Genome Sciences, senior management team will present,a ... am Eastern,Time., Investors interested in listening to the ...
... physicians credentialed,to practice at the Texas Institute for Surgery ... at its annual Best Doctors event., "Texas Institute ... in the country and it is a tremendous honor ... this prestigious list. The physicians who,operate at TIS are ...
Cached Biology Technology:China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40% 2Annual List of 'Best Doctors in Dallas' Showcases Texas Institute for Surgery Physicians 2
(Date:8/22/2014)... Thanks to important discoveries in basic and clinical ... has mobilized into a complex offensive spanning multiple ... Alberta chemistry lab could help find new and ... a compound that targets a specific enzyme overexpressed ... in cells from brain tumours. , Chemistry professor ...
(Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
... and philosophers across the nation are protesting a new ... a letter sent Monday to U.S. Secretary of the ... Public Works, and the House Committee on Natural Resources, ... legal opinion from the Solicitor of the U.S. Department ...
... to a new brain study, even people who seemed resilient but ... toppled on Sept. 11, 2001, have brains that are more reactive ... away. , That is the finding of a new Cornell study ... post-traumatic stress disorder (PTSD) or major depression. One of the first ...
... launched to try to boost the income of the world’s ... provide consumers with more nutritious, better tasting food. , New ... rice varieties that could fetch a higher price from consumers, ... The main aim of the new International Network for Quality ...
Cached Biology News:Legal ruling may put endangered species in danger 2Traumas like Sept. 11 make brains more reactive to fear 2New knowledge improves rice quality 2
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
...
Biology Products: